94 related articles for article (PubMed ID: 19851354)
1. An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.
Lai MD; Chen CS; Yang CR; Yuan SY; Tsai JJ; Tu CF; Wang CC; Yen MC; Lin CC
Cancer Gene Ther; 2010 Mar; 17(3):203-11. PubMed ID: 19851354
[TBL] [Abstract][Full Text] [Related]
2. An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.
Yen MC; Weng TY; Chen YL; Lin CC; Chen CY; Wang CY; Chao HL; Chen CS; Lai MD
Cancer Gene Ther; 2013 Jun; 20(6):351-7. PubMed ID: 23681283
[TBL] [Abstract][Full Text] [Related]
3. Trichostatin-A enhances adaptive immune responses to DNA vaccination.
Vanniasinkam T; Ertl H; Tang Q
J Clin Virol; 2006 Aug; 36(4):292-7. PubMed ID: 16765083
[TBL] [Abstract][Full Text] [Related]
4. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
[TBL] [Abstract][Full Text] [Related]
5. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine.
Arai H; Xin KQ; Hamajima K; Lu Y; Watabe S; Takahashi T; Toda S; Okuda K; Kudoh I; Suzuki M; Okuda K
Gene Ther; 2000 Apr; 7(8):694-702. PubMed ID: 10800093
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
Chan T; Sami A; El-Gayed A; Guo X; Xiang J
Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
[TBL] [Abstract][Full Text] [Related]
7. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
[TBL] [Abstract][Full Text] [Related]
10. [Construction of eukaryotic expression vector of mouse alpha-fetoprotein cDNA and its expression in dendritic cells and in vitro antitumor effect on hepatoma].
Zeng B; Lu FG; Liu XW; Yang DY; Fang WY; Wang J; Liao AJ; Shi W
Ai Zheng; 2005 Nov; 24(11):1332-7. PubMed ID: 16552958
[TBL] [Abstract][Full Text] [Related]
11. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
[TBL] [Abstract][Full Text] [Related]
12. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV.
Jounai N; Okuda K; Kojima Y; Toda Y; Hamajima K; Ohba K; Klinman D; Xin KQ
J Gene Med; 2003 Jul; 5(7):609-17. PubMed ID: 12825200
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine.
Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA
Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
17. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration.
Hattori Y; Kawakami S; Lu Y; Nakamura K; Yamashita F; Hashida M
J Gene Med; 2006 Jul; 8(7):824-34. PubMed ID: 16625665
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
19. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
[TBL] [Abstract][Full Text] [Related]
20. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2.
Rittich S; Duskova M; Mackova J; Pokorna D; Jinoch P; Smahel M
Oncol Rep; 2005 Feb; 13(2):311-7. PubMed ID: 15643517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
